Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharvaris Netherlands B.V.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed and dated informed consent form
Diagnosis of HAE type I or II
Documented history of at least 3 HAE attacks within the last 3 consecutive months prior to screening, or a minimum of 2 HAE attacks during the screening period
Reliable access and experience to use standard of care acute attack medications
You may not be if
Pregnancy or breast-feeding
Clinically significant abnormal electrocardiogram
Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study
Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrolment
Abnormal hepatic function
Abnormal renal function
History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse
Participation in any other investigational drug study within defined period
Clareo Health | Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
